Core Viewpoint - Microchip Technology Incorporated anticipates net sales for the third quarter of fiscal 2026 to reach approximately $1,185 million, exceeding previous guidance [1] Group 1: Financial Performance - The expected net sales of $1,185 million is significantly higher than the original guidance of $1,109 million to $1,149 million provided on November 6, 2025, and the revised guidance of being on the high end of the original range given on December 2, 2025 [1] - Strong bookings activity was reported for the December quarter, indicating robust demand despite the holiday season [2] Group 2: Recovery Plan and Strategic Initiatives - The company has made substantial progress on its nine-point recovery plan, which includes inventory correction and ramping up production in factories [2] - A significant reduction in internal inventory is expected to lower inventory write-offs, contributing positively to financial performance [2] - The company is optimistic about the calendar year 2026, anticipating benefits from the successful execution of its recovery plan [3] Group 3: Market Position and Operations - Microchip Technology is recognized as a leading provider of smart, connected, and secure embedded control solutions, serving various markets including industrial, automotive, consumer, aerospace, and defense [7] - The company is headquartered in Chandler, Arizona, and emphasizes innovative design solutions to address challenges in emerging technologies [7]

Core Viewpoint - Poxel SA is implementing a recovery plan to stabilize its financial situation and avoid liquidation, with new management focused on cost control and business development [3][5][6]. Recovery Plan Update - The recovery plan has been finalized, emphasizing commercial development for Imeglimine, PXL 770, and PXL 065, alongside significant cost reductions and clearing of liabilities [4][5]. - New financing commitments of up to €11.25 million from financial partners IPF and IRIS are aimed at supporting the recovery efforts [5][7]. - The plan requires approval from the Commercial Court of Lyon and will be presented to shareholders at the annual general meeting on December 11, 2025 [5][11]. Financial Structure and Capital Transactions - The recovery plan includes a capital increase with preferential subscription rights for existing shareholders, expected to be at a discount of 30% to 50% of the current share price [12][26]. - A capital increase reserved for IPF will be at a premium of 5% to 10% compared to the preferential subscription rights price [12][26]. - The restructuring aims to ensure that IPF retains approximately 29.9% of the company's share capital post-transaction [17][24]. Management and Strategic Focus - The new management team has been actively working since August to streamline operations and focus on core business areas, including potential partnerships for Imeglimine in Asia [6][9]. - The company plans to reduce administrative costs by transferring its listing to Euronext Growth, which will lower regulatory expenses [10][12]. Shareholder Engagement - A webinar is scheduled for November 26, 2025, to discuss the recovery plan and future prospects with shareholders [5][32]. - Shareholders will have the opportunity to vote on the proposed financial delegations and capital transactions during the upcoming general meeting [11][12].